By Jared S. Hopkins
Abbott Laboratories forecasts an impact of "a few hundred million dollars" this year from Trump administration tariffs, Chief Executive Robert Ford told analysts Wednesday.
The healthcare company sees the costs starting in the third quarter. Ford told analysts it is too early to simply double the 2025 estimate for how tariffs might affect Abbott in future years, but the company can cover them in the near term.
Illinois-based Abbott's products include baby formula and medical devices, with some devices imported from overseas. The company is studying how to mitigate tariffs long term, and expects its global manufacturing network to help with those efforts, Ford said.
"One thing we have learned from tariffs is they don't go away, so whatever comes it stays, and it stays for a while," he said. "Look at the tariffs that went in place in 2017. They're still there."
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
April 16, 2025 11:19 ET (15:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。